Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
The chart shows the growth of an initial investment of $10,000 in Centene Corporation, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Centene Corporation (CNC) has returned -14.74% so far this year and -43.04% over the past 12 months. Looking at the last ten years, CNC has achieved an annualized return of 1.21%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
CNC
1M-21.30%
6M-9.23%
YTD-14.74%
1Y-43.04%
5Y-10.96%
10Y1.21%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Centene Corporation (CNC) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
5.20%
5.18%
-25.98%
8.30%
2025
4.78%
-8.84%
4.08%
-1.32%
-5.10%
-1.49%
-52.01%
10.84%
22.49%
-1.06%
11.51%
5.43%
2024
0.41%
4.35%
0.54%
-6.66%
-1.00%
-7.14%
16.00%
1.76%
-4.50%
-17.30%
-3.72%
0.45%
2023
-7.02%
-10.05%
-6.87%
6.69%
-9.43%
7.59%
1.45%
-9.54%
11.19%
0.45%
7.23%
0.91%
2022
-6.47%
5.88%
2.36%
-5.19%
0.56%
3.31%
9.73%
-3.66%
-13.01%
8.53%
2.16%
-6.18%
2021
-0.51%
-2.84%
8.30%
-3.29%
19.77%
-1.27%
-6.19%
-8.22%
-1.70%
13.67%
1.45%
13.97%
2020
-0.27%
-16.25%
11.03%
18.13%
1.38%
-3.77%
2.00%
-6.60%
-4.56%
1.27%
2.72%
-3.98%
2019
14.47%
-6.38%
-13.70%
-3.93%
12.38%
-1.98%
-1.81%
-10.35%
-6.40%
22.02%
13.24%
4.23%
2018
6.49%
-5.21%
5.42%
1.03%
7.72%
4.44%
6.12%
11.60%
-1.11%
-10.25%
8.33%
-19.79%
2017
10.55%
11.36%
-0.56%
4.33%
-2.38%
9.89%
-0.72%
11.86%
8.85%
-3.56%
8.50%
-1.47%
2016
1.29%
0.48%
15.11%
-0.63%
-3.02%
-1.70%
-6.16%
-8.07%
-1.60%
Performance Indicators
The charts below present risk-adjusted performance metrics for Centene Corporation (CNC) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CNC compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Centene Corporation volatility is 4.22%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Liabilities And Equity (USD)
76.75B
82.45B
84.64B
76.87B
78.38B
68.72B
40.99B
30.90B
21.86B
20.20B
7.34B
5.84B
3.53B
2.74B
2.19B
Temporary Equity (USD)
23.00M
10.00M
19.00M
56.00M
82.00M
77.00M
33.00M
10.00M
12.00M
145.00M
156.00M
148.00M
-
-
-
Equity Attributable To Parent (USD)
19.95B
26.41B
25.84B
24.06B
26.80B
25.77B
12.55B
10.92B
6.85B
5.90B
2.16B
1.74B
1.23B
953.06M
935.63M
Equity Attributable To Noncontrolling Interest (USD)
Ten large-cap stocks experienced significant declines during the week of March 9-13, 2026. Fair Isaac Corporation led losses with a 21.59% drop following a $1 billion senior notes offering announcement. Other major decliners included Centene (20.85%), Ulta Beauty (16.04%), Paramount Skydance (15.4%), and Thomson Reuters (13.97%). Declines were attributed to factors including disappointing earnings guidance, analyst downgrades, and broader market pressures across healthcare, beauty, media, and aviation sectors.
U.S. stocks rallied Tuesday as crude oil plummeted 10% to $85/barrel following President Trump's signals that the Iran conflict may be ending soon and his commitment to keep the Strait of Hormuz safe. The S&P 500 rose 0.3%, Dow gained 0.4%, and Nasdaq 100 advanced 0.5%, while the VIX dropped 9.3% signaling reduced market fear.
Benzinga•Piero Cingari
AI Insight
Stock declined 10.5%, making it the worst performer among Russell 1000 stocks on the day.
The healthcare transportation service market is expected to grow from $116.47 billion in 2026 to $155.26 billion by 2030, with a CAGR of 7.5%. Growth drivers include aging populations, chronic disease prevalence, home healthcare expansion, and AI-powered route optimization. Leading companies include Centene, Molina Healthcare, DHL, ARAMARK, Lyft Healthcare, and ModivCare, with North America currently dominant and Asia-Pacific showing fastest growth.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
Listed as a leading company in the growing healthcare transportation service market, positioned to benefit from projected 7.5% CAGR growth through 2030.
Centene Corporation reported mixed fourth-quarter 2025 results with revenue beating expectations at $49.73 billion, but the stock fell 5.87% due to a weak 2026 outlook. The company faced challenges from declining Medicaid membership (down to 12.52 million from 13.00 million) and a higher health benefits ratio of 94.3%, though it expects adjusted EPS above $3.00 for 2026.
Benzinga•Vandana Singh
AI Insight
Stock declined 5.87% despite beating revenue expectations. The decline was driven by shrinking Medicaid membership, elevated health benefits ratio (94.3%, up from 89.6%), and lower 2026 sales guidance ($186.5B-$190.5B vs. consensus $193.43B), indicating operational challenges and margin pressures despite positive EPS guidance.
Philip Morris International significantly exceeded earnings expectations with EPS of $7.54 vs. $1.70 expected and revenue of $10.4B vs. $10.39B expected, driven by strong growth in smoke-free products. Biogen also beat estimates with EPS of $1.99 vs. $1.61 expected, boosted by strong sales of LEQEMBI and SKYCLARYS. Centene reported mixed results but beat both EPS and revenue expectations. All three companies provided positive 2026 guidance.
Investing.com•Timothy Fries
AI Insight
Reported mixed results with EPS beat (-$1.19 vs -$1.22 expected) and revenue beat ($49.73B vs $48.39B expected), but faced a challenging year. However, strategic initiatives showing positive results with 2026 guidance of adjusted diluted EPS greater than $3.00.
The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.
Benzinga•Vandana Singh
AI Insight
Stock declined 7.26% as the lower-than-expected payment increase affects Medicaid and Medicare Advantage revenue streams.
Leverage Shares by Themes launched seven new 2X leveraged single-stock ETFs on December 18, 2025, offering 200% daily performance exposure to stocks including Nio, Snap, Baidu, Centene, KLA, Petrobras, and Vale. These products carry a 0.75% expense ratio and are designed for short-term traders rather than long-term investors. The expansion brings Leverage Shares' total single-stock daily leveraged ETF offerings to 60.
Benzinga•Chandrima Sanyal
AI Insight
Centene is included in the new ETF launch as an underlying asset with no company-specific news or developments mentioned.
BofA Securities highlighted Cigna's strong potential in commercial health insurance, noting its pharmacy benefit management platform and ability to deliver 10-15% annual EPS growth, while also discussing challenges and opportunities in the healthcare insurance market.
Benzinga•Vandana Singh
AI Insight
Facing challenges with Medicaid enrollment declines, uncertain exchange risk pricing, and limited near-term market reward potential
Centene, a healthcare insurance company managing government-sponsored health programs, could see stock gains if ACA subsidies are extended in December. The stock has rebounded after a significant drop in July and shows potential for growth.
The Motley Fool•Matthew Benjamin
AI Insight
Stock has rebounded almost 19% in the past month, beat earnings expectations, lowered medical costs, and could benefit from potential ACA subsidy extensions
The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.
Benzinga•Vandana Singh
AI Insight
Healthcare policy framework could create uncertainty in insurance sector
